USFDA gives nod for this generic drug for urinary issues

The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, the filing added.

110

Last Updated on December 31, 2023 by The Health Master

New Delhi: Zydus Lifesciences said it has received the USFDA’s final nod to market its generic version of Mirabegron extended-release tablets used to treat overactive bladder, with 180 days of shared generic drug exclusivity.

The final approval granted by the US Food and Drug Administration (USFDA) to the company’s US arm, Zydus Pharmaceuticals, Inc., is for the tablets of strengths of 25 mg and 50 mg, it said in a regulatory filing.

Zydus was one of the first applicants to submit a substantially complete ANDA (abbreviated new drugs application) with a paragraph IV certification for Mirabegron extended-release tablets, 25 mg, and 50 mg, and is, therefore, eligible for 180 days of shared generic drug exclusivity for the drug, it added.

Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and urinary frequency.

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, the filing added.

As per IQVIA MAT August 2022 data, Zydus said Mirabegron extended-release tablets 25mg and 50mg had annual sales of USD 2.42 billion in the US.

USFDA gives approval for Sildenafil for oral suspension

USFDA approved this drug to prevent nerve cells dying prematurely

USFDA approves Mirabegron extended-release tablets

USFDA gives nod for this generic non-steroidal anti-inflammatory drug

USFDA approves Intravenous therapy for hearing loss

USFDA approves Terlipressin for injection to treat Kidney function

IPC launches 1000th IP Reference Standard

NDPS: Inter-state Pharmaceutical drug racket busted

USFDA issues 2 observations on Form 483 to Zydus Lifesciences

DCGI panel recommends ban on these Fixed dose combination drugs

Bar codes could come soon to stop the threat of sub-standard drugs

Govt notifies RDTL Chandigarh as Central Medical Devices Testing Laboratory

Drug recall: Acyclovir Sodium Injection recalled due to this reason

Changing the Regulations for Class A Medical Devices and its Impact

Govt plan to ban Codeine based cough syrups opposed by Pharma companies

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news